1-8 of 8
Il-Kyoo Park
Close
Sort by
Journal Articles

TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition

Jae Yoon Jeon, PharmD, Il-Kyoo Park, PhD, Daelynn R Buelow, PhD, Clifford Whatcott, PhD, Steven L. Warner, PhD, William Blum, MD, Sharyn Baker, PharmD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2522.
https://doi.org/10.1182/blood.V130.Suppl_1.2522.2522
Published: 2017
Journal Articles

The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia

Il-Kyoo Park, PhD, Bethany Mundy-Bosse, PhD, Steven L. Warner, PhD, David J. Bearss, PhD, Guido Marcucci, MD, Michael A. Caligiuri, MD
Journal: Blood
Blood (2014) 124 (21): 2350.
https://doi.org/10.1182/blood.V124.21.2350.2350
Published: 2014
Journal Articles

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

Il-Kyoo Park, Anjali Mishra, Jason Chandler, Susan P. Whitman, Guido Marcucci, Michael A. Caligiuri
Journal: Blood
Blood (2013) 121 (11): 2064–2073.
https://doi.org/10.1182/blood-2012-07-444018
Published: 2013
Includes: Supplemental data
Journal Articles

Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance)

Susan Whitman, PhD, Jessica Kohlschmidt, PhD, Kati Maharry, MAS, Deedra Nicolet, MS, Sebastian Schwind, MD, Heiko Becker, MD, Klaus H. Metzeler, MD, Krzysztof Mrózek, MD, PhD, Jason H. Mendler, MD, PhD, Ann-Kathrin Eisfeld, MD, Stefano Volinia, PhD, Bayard L. Powell, MD, Thomas H. Carter, MD, PhD, Jonathan E. Kolitz, MD, Richard M. Stone, MD, Il-Kyoo Park, Michael A. Caligiuri, M.D., Guido Marcucci, MD, Clara D. Bloomfield, MD
Journal: Blood
Blood (2012) 120 (21): 1293.
https://doi.org/10.1182/blood.V120.21.1293.1293
Published: 2012
Journal Articles

Effective Targeting of Acute Myeloid Leukemia (AML) Harboring the FLT3 ITD Mutation through the Axl/Gas6 Pathway

Il-Kyoo Park, Anjali Mishra, Jason C. Chandler, Michael A. Caligiuri
Journal: Blood
Blood (2010) 116 (21): 500.
https://doi.org/10.1182/blood.V116.21.500.500
Published: 2010
Journal Articles

CD94 surface density identifies a functional intermediary between the CD56 bright and CD56 dim human NK-cell subsets

Jianhua Yu, Hsiaoyin C. Mao, Min Wei, Tiffany Hughes, Jianying Zhang, Il-kyoo Park, Shujun Liu, Susan McClory, Guido Marcucci, Rossana Trotta, Michael A. Caligiuri
Journal: Blood
Blood (2010) 115 (2): 274–281.
https://doi.org/10.1182/blood-2009-04-215491
Published: 2010
Includes: Supplemental data
Journal Articles

The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development

Il-Kyoo Park, Chiara Giovenzana, Tiffany L. Hughes, Jianhua Yu, Rossana Trotta, Michael A. Caligiuri
Journal: Blood
Blood (2009) 113 (11): 2470–2477.
https://doi.org/10.1182/blood-2008-05-157073
Published: 2009
Journal Articles

The Axl/Gas6 Pathway Is Required for Human Natural Killer Cell Development.

Il-Kyoo Park, Chiara Giovenzana, Tiffany L. Hughes, Jianhua Yu, Rossana Trotta, Michael A. Caligiuri
Journal: Blood
Blood (2007) 110 (11): 2305.
https://doi.org/10.1182/blood.V110.11.2305.2305
Published: 2007